Global Non-melanoma Skin Cancer Market 2014-2018

非黒色腫皮膚がん治療のグローバル市場(2014-2018)

◆タイトル:Global Non-melanoma Skin Cancer Market 2014-2018
◆商品コード:IRTNTR3605
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年5月23日
◆ページ数:119
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥363,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"非黒色腫皮膚がん治療のグローバル市場(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、種類別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Non-melanoma Skin Cancer
Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Non-melanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT.
TechNavio’s analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments:
• Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis
• Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy

TechNavio’s report, the Global Non-melanoma Skin Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and, the EMEA and the APAC region; and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Elekta AB
• F. Hoffmann-la Roche Ltd.
• iCAD Inc.
• Meda AB
• Valeant Pharmaceuticals Inc.
• Varian Medical Systems Inc.

Other Prominent Vendors

• Aqua Pharmaceuticals LLC
• Almirall SA
• Biofrontera AG
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb Co.
• Cannabis Science Inc.
• Cellceutix Corp.
• Eli Lilly and Co.
• Galderma SA
• GENEXTRA SpA
• IRX Therapeutics Inc.
• LEO Pharma A/S
• Merck & Co. Inc.
• Moberg Pharma AB
• Mylan Pharmaceutical Inc.
• Novartis International AG
• Oncothyreon Inc.
• Sun Pharma Industries Ltd.

Market Driver
• Increasing Incidence of Non-melanoma Skin Cancer
• For a full, detailed list, view our report.

Market Challenge
• Availability of Alternative Treatments
• For a full, detailed list, view our report.

Market Trend
• Emergence of Combination Therapies
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
More Information about Global Non-melanoma Skin Cancer Market

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Global Non-melanoma Skin Cancer Drugs Market
06.3.1 Market Size and Forecast
06.4 Global Actinic Keratosis Drugs Market
06.4.1 Market Overview
06.4.2 Market Size and Forecast
06.5 Top Selling Drugs for the Treatment of BCC, SCC, and Actinic Keratosis
06.6 Five Forces Analysis
07. Market Segmentation by Type
07.1 Global Non-melanoma Skin Cancer Drugs Market by Type
07.1.1 BCC
07.1.2 SCC
07.2 Global BCC Drugs Market
07.2.1 Market Size and Forecast
07.3 Global SCC Drugs Market
07.3.1 Market Size and Forecast
08. Pipeline Analysis
09. Geographical Segmentation
09.1 Global Non-melanoma Skin Cancer Market by Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Market Share Analysis 2013
17.2 Global Actinic Keratosis Drugs Market
17.3 Other Prominent Vendors
18. Non-invasive Treatment Market
18.1 Global Non-melanoma Skin Cancer Radiotherapy Market
18.1.1 Market Size and Forecast
18.2 Global Non-melanoma Skin Cancer Cryotherapy Market
18.2.1 Market Size and Forecast
18.3 Global Non-melanoma Skin Cancer PDT Market
18.3.1 Market Size and Forecast
18.4 Global Non-melanoma Skin Cancer Laser Therapy Market
18.4.1 Market Size and Forecast
18.5 Vendor Share
18.5.1 Global Non-melanoma Skin Cancer Radiotherapy Equipment Market
18.5.2 Global Non-melanoma Skin Cancer Cryotherapy Equipment Market
18.5.3 Global Non-melanoma Skin Cancer PDT Equipment Market
18.5.4 Global Non-melanoma Skin Cancer Laser Equipment Market
19. Key Vendor Analysis
19.1 Elekta AB
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Product Categorization
19.1.4 Revenue by Product Offerings
19.1.5 Revenue Comparison by Geographical Segmentation 2012 and 2013
19.1.6 Revenue Comparison by Geographical Segmentation
19.1.7 Business Strategy
19.1.8 Key Developments
19.1.9 SWOT Analysis
19.1.10 Strengths
19.1.11 Weaknesses
19.1.12 Opportunities
19.1.13 Threats
19.2 F. Hoffmann-La Roche Ltd.
19.2.1 Key Facts
19.2.2 Business Description
19.2.3 Business Segmentation
19.2.4 Revenue by Business Segmentation
19.2.5 Geographical Sales Segmentation by Business Segments
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.2.9 Strengths
19.2.10 Weaknesses
19.2.11 Opportunities
19.2.12 Threats
19.3 iCAD Inc.
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison by Business Segmentation 2012 and 2013
19.3.6 Revenue by Geographical Segmentation
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
19.3.10 Strengths
19.3.11 Weaknesses
19.3.12 Opportunities
19.3.13 Threats
19.4 Meda AB
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Product Segmentation
19.4.4 Revenue by Product Segmentation
19.4.5 Revenue Comparison by Product Segmentation 2012 and 2013
19.4.6 Revenue by Geographical Segmentation
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
19.4.10 Strengths
19.4.11 Weaknesses
19.4.12 Opportunities
19.4.13 Threats
19.5 Valeant Pharmaceuticals International Inc.
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue Comparison by Business Segmentation 2011-2013
19.5.5 Revenue by Geographical Segmentation
19.5.6 Business Strategy
19.5.7 Key Developments
19.5.8 SWOT Analysis
19.5.9 Strengths
19.5.10 Weaknesses
19.5.11 Opportunities
19.5.12 Threats
19.6 Varian Medical Systems Inc.
19.6.1 Key Facts
19.6.2 Business Description
19.6.3 Business Segmentation
19.6.4 Revenue by Business Segmentation
19.6.5 Revenue Comparison by Business Segmentation 2013 and 2012
19.6.6 Revenue by Geographical Segmentation
19.6.7 Business Strategy
19.6.8 Key Developments
19.6.9 SWOT Analysis
19.6.10 Strengths
19.6.11 Weaknesses
19.6.12 Opportunities
19.6.13 Threats
20. Other Reports in this Series


List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Global Non-melanoma Skin Cancer Market Segmentation by Type
Exhibit 3: Global Non-melanoma Skin Cancer Market 2013-2020 (US$ million)
Exhibit 4: Global Non-melanoma Skin Cancer Drugs Market 2013-2020 (US$ million)
Exhibit 5: Global Actinic Keratosis Drugs Market 2013-2020 (US$ million)
Exhibit 6: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type
Exhibit 7: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type 2013
Exhibit 8: Global BCC Drugs Market 2013-2020 (US$ million)
Exhibit 9: Global SCC Drugs Market 2013-2020 (US$ million)
Exhibit 10: Global Non-melanoma Skin Cancer Market by Geographical Segmentation 2013
Exhibit 11: Global Actinic Keratosis Drugs Market by Vendor Segmentation 2013
Exhibit 12: Global Non-melanoma Skin Cancer Radiotherapy Market 2013-2020 (US$ million)
Exhibit 13: Global Non-melanoma Skin Cancer Cryotherapy Market 2013-2020 (US$ million)
Exhibit 14: Global Non-melanoma Skin Cancer PDT Market 2013-2020 (US$ million)
Exhibit 15: Global Non-melanoma Skin Cancer Laser Therapy Market 2013-2020 (US$ million)
Exhibit 16: Global Non-melanoma Skin Cancer Radiotherapy Equipment Market by Vendor Segmentation 2013
Exhibit 17: Global Non-melanoma Skin Cancer Cryotherapy Equipment Market by Vendor Segmentation 2013
Exhibit 18: Global Non-melanoma Skin Cancer PDT Equipment Market by Vendor Segmentation 2013 51
Exhibit 19: Vendors in Global Non-melanoma Skin Cancer Laser Equipment Market
Exhibit 20: Elekta AB: Product Categorization
Exhibit 21: Elekta AB: Revenue by Product Offerings 2013
Exhibit 22: Elekta AB: Revenue Comparison by Geographical Segmentation 2012 and 2013 (US$ million)
Exhibit 23: Elekta AB: Revenue Comparison by Geographical Segmentation 2013
Exhibit 24: F. Hoffmann-la Roche Ltd.: Business Segmentation 2013
Exhibit 25: F. Hoffmann-la Roche Ltd.: Revenue by Business Segmentation 2012 and 2013
Exhibit 26: F. Hoffmann-la Roche Ltd.: Revenue of Pharmaceuticals Division by Geographical Segmentation 2013
Exhibit 27: F. Hoffmann-la Roche Ltd.: Revenue of Diagnostics Division by Geographical Segmentation 2013
Exhibit 28: iCAD Inc.: Business Segmentation
Exhibit 29: iCAD Inc.: Revenue by Business Segmentation 2013
Exhibit 30: iCAD Inc.: Revenue Comparison by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 31: iCAD Inc.: Revenue by Geographical Segmentation 2013
Exhibit 32: Meda AB: Product Segmentation
Exhibit 33: Meda AB: Revenue by Product Segmentation 2013
Exhibit 34: Meda AB: Revenue Comparison by Product Segmentation 2012 and 2013 (US$ billion)
Exhibit 35: Meda AB: Revenue by Geographical Segmentation 2013
Exhibit 36: Valeant Pharmaceuticals International Inc.: Business Segmentation 2013
Exhibit 37: Valeant Pharmaceuticals International Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ million)
Exhibit 38: Valeant Pharmaceuticals International Inc.: Revenue by Geographical Segmentation 2013
Exhibit 39: Varian Medical Systems Inc.: Business Segmentation
Exhibit 40: Varian Medical Systems Inc.: Revenue by Business Segmentation 2013
Exhibit 41: Varian Medical Systems Inc.: Revenue Comparison by Business Segmentation (US$ million)
Exhibit 42: Varian Medical Systems Inc.: Revenue Segmentation by Geographical Segmentation 2013



【掲載企業】

Elekta AB, F. Hoffmann-la Roche Ltd., iCAD Inc., Meda AB, Valeant Pharmaceuticals Inc., Varian Medical Systems Inc., Aqua Pharmaceuticals LLC, Almirall SA, Biofrontera AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Cannabis Science Inc., Cellceutix Corp., Eli Lilly and Co., Galderma SA, GENEXTRA SpA, IRX Therapeutics Inc., LEO Pharma A/S, Merck & Co. Inc., Moberg Pharma AB,Mylan Pharmaceutical Inc, Novartis International AG, Oncothyreon Inc., Sun Pharma Industries Ltd.

【資料のキーワード】

非黒色腫皮膚がん、非メラノーマ性皮膚がん、皮膚癌

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[非黒色腫皮膚がん治療のグローバル市場(2014-2018)] (Global Non-melanoma Skin Cancer Market 2014-2018 / IRTNTR3605)販売に関する免責事項
[非黒色腫皮膚がん治療のグローバル市場(2014-2018)] (Global Non-melanoma Skin Cancer Market 2014-2018 / IRTNTR3605)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆